Zai Lab Receives U.S. FDA Fast Track Designation For Zl-1310, A Dll3-Targeted Antibody-Drug Conjugate, For Treatment Of Extensive-Stage Small Cell Lung Cancer
May 19 (Reuters) - Zai Lab Ltd 9688.HK:
ZAI LAB RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR ZL-1310, A DLL3-TARGETED ANTIBODY-DRUG CONJUGATE, FOR TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
ZAI LAB LTD - TO INITIATE PIVOTAL STUDY FOR ZL-1310 IN 2025
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.